Recent Finacing
Recent Raise
Dermaliq develops topical therapeutics using proprietary hyliQ™ cutaneous delivery technology, holds Novaliq‑licensed IP, and is advancing Phase 1/2a programs for androgenetic alopecia, plaque psoriasis, and skin infections.
